Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9190963 | 1.00 | POLB (0.55) | POLBGLARAB9ANPC1CYP11B1 | |
| SCHEMBL4468681 | 1.00 | POLB (0.55) | POLBGLARAB9ANPC1CYP11B1 | |
| SCHEMBL2252180 | 0.82 | ALDH1A1 (0.56) | POLBRAB9ANPC1CYP11B1CYP11B2 | |
| SCHEMBL2252176 | 0.82 | ALDH1A1 (0.56) | POLBRAB9ANPC1CYP11B1CYP11B2 | |
| SCHEMBL2252182 | 0.82 | ALDH1A1 (0.56) | POLBRAB9ANPC1CYP11B1CYP11B2 | |
| SCHEMBL9860368 | 0.80 | GABRA1 (0.48) | POLBRAB9ANPC1ALDH1A1GABRA1 | |
| SCHEMBL9860364 | 0.80 | GABRA1 (0.48) | POLBRAB9ANPC1ALDH1A1GABRA1 | |
| SCHEMBL2251853 | 0.79 | RAB9A (0.56) | RAB9ANPC1CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL6505265 | 0.79 | POLB (0.60) | POLBGLACYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL5633899 | 0.79 | POLB (0.60) | POLBGLACYP11B1CYP11B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831180-B1 | PYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-1831180-B1 | PYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| US-7589088-B2 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589088-B2 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589088-B2 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1831180-A2 | PYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | Bristol-Myers Squibb Company (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006071762-A2 | PYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-29 | — | — | US | disclosed |
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-29 | — | — | US | disclosed |
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | POLB 55/4885GLA 1305/4885RAB9A 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.